Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
A Multicenter Non Interventional Single Arm Retrospective-prospective Observational Study in Therapeutic Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis (gMG) in Real Clinical Practice in Russia
AstraZeneca
450 participants
Dec 23, 2025
OBSERVATIONAL
Conditions
Summary
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.
Eligibility
Inclusion Criteria2
- Adults (≥18 years) diagnosed with generalized MG positive for acetylcholine receptor (AChR) antibodies.
- Provision of signed and dated written informed consent.
Exclusion Criteria2
- Participants currently enrolled in clinical studies for treatment of gMG.
- Ocular MG only.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07247279